Tutorials
OCSE:GMAB (Denmark)  
Genmab A/S logo

Genmab A/S

kr 2583.00 (+0.51%) Aug 10
On watch
P/E:
71.79
P/B:
7.47
Market Cap:
kr 168.68B ($ 23.38B)
Enterprise V:
kr 149.10B ($ 20.67B)
Volume:
107.75K
Avg Vol (2M):
109.00K
Also Trade In:
Volume:
107.75K
Market Cap kr:
168.68B
Market Cap $:
23.38B
PE Ratio:
71.79
Avg Vol (2-Month):
109.00K
Enterprise Value kr:
149.10B
Enterprise Value $:
20.67B
PB Ratio:
7.47
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Description
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.
Name Current Vs Industry Vs History
Cash-To-Debt 48.05
Equity-to-Asset 0.91
Debt-to-Equity 0.02
Debt-to-EBITDA 0.11
Interest Coverage 4.5
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 48.62
Distress
Grey
Safe
Beneish M-Score -1.95
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 53.68
9-Day RSI 55.94
14-Day RSI 58.66
6-1 Month Momentum % 11.29
12-1 Month Momentum % -13.1

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 17.31
Quick Ratio 17.31
Cash Ratio 14.93
Days Sales Outstanding 110.93

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.3

Financials (Next Earnings Date:2022-11-09)

OCSE:GMAB's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 9,020
EPS (TTM) (kr) 35.98
Beta 1.58
Volatility % 33.95
14-Day RSI 58.66
14-Day ATR (kr) 72.727812
20-Day SMA (kr) 2575.55
12-1 Month Momentum % -13.1
52-Week Range (kr) 1863 - 3124
Shares Outstanding (Mil) 65.3

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Genmab A/S Filings

Document Form Filing Date
No Filing Data